A Study of Olverembatinib in the Treatment of Ph+ ALL

Clinical trial NCT05466175 · UNKNOWN

Trial details

NCT number: NCT05466175
Sponsor: Chen Suning
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Philadelphia-Positive ALL

Start date: 2022-10-01
Primary completion: 2023-09-30
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.